Page last updated: 2024-11-04

2,3-dihydroxybenzoic acid

Description Research Excerpts Clinical Trials Roles Classes Pathways Study Profile Bioassays Related Drugs Related Conditions Protein Interactions Research Growth Market Indicators

Description

2,3-dihydroxybenzoic acid: RN given refers to parent cpd [Medical Subject Headings (MeSH), National Library of Medicine, extracted Dec-2023]

dihydroxybenzoic acid : Any member of the class of hydroxybenzoic acids carrying two phenolic hydroxy groups on the benzene ring and its derivatives. [Chemical Entities of Biological Interest (ChEBI), Hastings J, Owen G, Dekker A, Ennis M, Kale N, Muthukrishnan V, Turner S, Swainston N, Mendes P, Steinbeck C. (2016). ChEBI in 2016: Improved services and an expanding collection of metabolites. Nucleic Acids Res]

2,3-dihydroxybenzoic acid : A dihydroxybenzoic acid that is benzoic acid substituted by hydroxy groups at positions 2 and 3. It occurs naturally in Phyllanthus acidus and in the aquatic fern Salvinia molesta. [Chemical Entities of Biological Interest (ChEBI), Hastings J, Owen G, Dekker A, Ennis M, Kale N, Muthukrishnan V, Turner S, Swainston N, Mendes P, Steinbeck C. (2016). ChEBI in 2016: Improved services and an expanding collection of metabolites. Nucleic Acids Res]

FloraRankFlora DefinitionFamilyFamily Definition
Salviniagenus[no description available]Salviniaceae[no description available]
PhyllanthusgenusA plant genus of the family EUPHORBIACEAE. Bahupatra (MEDICINE, AYURVEDIC) is prepared from this.[MeSH]Phyllanthaceae[no description available]
Phyllanthus acidusspecies[no description available]Phyllanthaceae[no description available]

Cross-References

ID SourceID
PubMed CID19
CHEMBL ID1432
CHEBI ID18026
SCHEMBL ID37458
MeSH IDM0053570

Synonyms (82)

Synonym
smr000471836
MLS001066375
pyrocatechuic acid
CHEBI:18026 ,
catechol-3-carboxylic acid
2-pyrocatechuic acid
dobk
o-pyrocatechuic acid
catecholcarboxylic acid
nsc-27435
benzoic acid,3-dihydroxy-
nsc27435
3-hydroxysalicylic acid
2,3 dhb
SDCCGMLS-0066859.P001
BSPBIO_003437
einecs 206-139-5
brn 2209117
nsc 27435
dhba
benzoic acid, 2,3-dihydroxy-
inchi=1/c7h6o4/c8-5-3-1-2-4(6(5)9)7(10)11/h1-3,8-9h,(h,10,11
2,3-dihydroxy-benzoic acid
2,3-dihydroxybenzoic acid
303-38-8
C00196
DB01672
1L6M
2,3-dihydroxybenzoic acid, 99%
KBIO3_002940
SPECTRUM3_001819
SPECTRUM2_001086
SPBIO_001132
NCGC00178064-01
FF124556-A828-490B-B324-9AE859B695FA
AC-2985
pyrocatechol-3-carboxylic acid
ksc-11-207-9
KUC106698N
2,3-dihydroxybenzoicacid
CHEMBL1432
dihydroxybenzoic acid
2,3-dihydroxy benzoic acid
4-10-00-01414 (beilstein handbook reference)
unii-70d5fbb392
70d5fbb392 ,
A820329
27138-57-4
resorcylic acid
benzoic acid, dihydroxy-
HMS2231J14
CCG-40337
2,3-dihydroxybenzoate, iv
bdbm92456
BP-12659
FT-0609669
PS-3013
3TF6
3U0D
AKOS009156763
HMS3369A12
SCHEMBL37458
1,2-dihydroxybenzene-3-carboxylic acid
SY003494
mfcd00002446
2,3 dihydroxy-benzoic acid
Q-200170
2,3-dihdroxybenzoic acid
DTXSID70858712
sr-01000761414
SR-01000761414-2
2,3-dihydroxybenzoic acid;catecholcarboxylic acid;nsc 27435
CS-W019844
catecholcarboxylate
pyrocatechuate
o-pyrocatechuate
HY-Y0202
Q2823200
AMY17988
S4946
EN300-112276
Z367679198

Research Excerpts

Toxicity

ExcerptReferenceRelevance
" Toxic effects of either metabolite were not evident beyond 24 h, and toxicity of 2,5-DIOH was significantly greater in comparison to 2,3-DIOH."( Comparative acute nephrotoxicity of salicylic acid, 2,3-dihydroxybenzoic acid, and 2,5-dihydroxybenzoic acid in young and middle aged Fischer 344 rats.
Birnbaum, LS; Blair, PC; Clark, AM; McMahon, TF; Stefanski, SA; Wilson, RE, 1991
)
0.53
" This study supports the idea that iron and free radicals play a critical role in the toxic side effects of aminoglycoside antibiotics."( Iron chelators protect from aminoglycoside-induced cochleo- and vestibulo-toxicity.
Schacht, J; Sha, SH; Song, BB, 1998
)
0.3
" Ototoxicity (loss of hearing or balance) is a well-documented adverse effect of aminoglycosides, and severe ototoxic reactions have been noted in patients receiving these drugs by intraperitoneal lavage."( Protection from ototoxicity of intraperitoneal gentamicin in guinea pig.
Schacht, J; Sha, SH; Sinswat, P; Wu, WJ, 2000
)
0.31
"One of the major adverse effects of vancomycin (VAN) is nephrotoxicity, which the mechanism is not fully understood."( The effect of 2,3-dihydroxybenzoic acid and tempol in prevention of vancomycin-induced nephrotoxicity in rats.
Ghafghazi, T; Hajhashemi, V; Naghibi, B; Taheri, D; Talebi, A, 2007
)
0.7

Compound-Compound Interactions

ExcerptReferenceRelevance
" Here we describe a rapid and sensitive HPLC method using ultraviolet absorbance (UV) and electrochemical detection (EC) to detect SA (UV), its hydroxylated adducts 2,3- and 2,5-dihydroxybenzoic acids (DHBA) and catechol in combination with catechol- and indoleamines and related metabolites (EC) in one isocratic run."( Detection of salicylate and its hydroxylated adducts 2,3- and 2,5-dihydroxybenzoic acids as possible indices for in vivo hydroxyl radical formation in combination with catechol- and indoleamines and their metabolites in cerebrospinal fluid and brain tissu
Gramsbergen, JB; Sloot, WN, 1995
)
0.29

Bioavailability

ExcerptReferenceRelevance
" However, the bioavailability of cocoa flavanols is very low and their bioactivity in vivo seems to be greatly mediated by the derived phenolic metabolites formed by intestinal microbiota."( Colonic metabolites from flavanols stimulate nitric oxide production in human endothelial cells and protect against oxidative stress-induced toxicity and endothelial dysfunction.
Álvarez-Cilleros, D; Goya, L; Martín, MÁ; Ramos, S, 2018
)
0.48

Dosage Studied

ExcerptRelevanceReference
" Effects of these treatments on functional integrity of renal tissue was assessed from 0--72 h after dosing by measurement of urinary creatinine, GLU, and PRO, as well as excretion of proximal and distal tubular renal enzymes."( Comparative acute nephrotoxicity of salicylic acid, 2,3-dihydroxybenzoic acid, and 2,5-dihydroxybenzoic acid in young and middle aged Fischer 344 rats.
Birnbaum, LS; Blair, PC; Clark, AM; McMahon, TF; Stefanski, SA; Wilson, RE, 1991
)
0.53
" The optimum dosage of SA and the appropriate sampling time for in vivo experiments was determined, and significant increases in the ratio of 2,3-DHBA to SA were detected in several organs of mice after X-irradiation."( Estimation of hydroxyl radical generation by salicylate hydroxylation method in multiple organs of mice exposed to whole-body X-ray irradiation.
Ito, N; Kashimoto, T; Nishimura, Y; Sugiyama, M; Susa, N; Takeda-Homma, S; Ueno, S; Wada, K, 2006
)
0.33
[information is derived through text-mining from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Roles (2)

RoleDescription
human xenobiotic metaboliteAny human metabolite produced by metabolism of a xenobiotic compound in humans.
plant metaboliteAny eukaryotic metabolite produced during a metabolic reaction in plants, the kingdom that include flowering plants, conifers and other gymnosperms.
[role information is derived from Chemical Entities of Biological Interest (ChEBI), Hastings J, Owen G, Dekker A, Ennis M, Kale N, Muthukrishnan V, Turner S, Swainston N, Mendes P, Steinbeck C. (2016). ChEBI in 2016: Improved services and an expanding collection of metabolites. Nucleic Acids Res]

Drug Classes (1)

ClassDescription
dihydroxybenzoic acidAny member of the class of hydroxybenzoic acids carrying two phenolic hydroxy groups on the benzene ring and its derivatives.
[compound class information is derived from Chemical Entities of Biological Interest (ChEBI), Hastings J, Owen G, Dekker A, Ennis M, Kale N, Muthukrishnan V, Turner S, Swainston N, Mendes P, Steinbeck C. (2016). ChEBI in 2016: Improved services and an expanding collection of metabolites. Nucleic Acids Res]

Pathways (3)

PathwayProteinsCompounds
2,3-Dihydroxybenzoate Biosynthesis411
Biosynthesis of Siderophore Group Nonribosomal Peptides1821
Enterobactin Biosynthesis514

Protein Targets (8)

Potency Measurements

ProteinTaxonomyMeasurementAverage (µ)Min (ref.)Avg (ref.)Max (ref.)Bioassay(s)
Chain A, JmjC domain-containing histone demethylation protein 3AHomo sapiens (human)Potency100.00000.631035.7641100.0000AID504339
[prepared from compound, protein, and bioassay information from National Library of Medicine (NLM), extracted Dec-2023]

Inhibition Measurements

ProteinTaxonomyMeasurementAverageMin (ref.)Avg (ref.)Max (ref.)Bioassay(s)
72 kDa type IV collagenaseHomo sapiens (human)IC50 (µMol)200.00000.00001.284810.0000AID1799773
MatrilysinHomo sapiens (human)IC50 (µMol)200.00000.00142.085910.0000AID1799773
Prolyl 4-hydroxylase subunit alpha-1Gallus gallus (chicken)Ki70.00005.00007.66679.0000AID1799825
4-galactosyl-N-acetylglucosaminide 3-alpha-L-fucosyltransferase FUT6Homo sapiens (human)IC50 (µMol)200.00000.06003.89568.3000AID1799773
Alpha-(1,3)-fucosyltransferase 7Homo sapiens (human)IC50 (µMol)200.00000.06003.89568.3000AID1799773
CMP-N-acetylneuraminate-beta-galactosamide-alpha-2,3-sialyltransferase 1Homo sapiens (human)IC50 (µMol)200.00000.06003.89568.3000AID1799773
[prepared from compound, protein, and bioassay information from National Library of Medicine (NLM), extracted Dec-2023]

Activation Measurements

ProteinTaxonomyMeasurementAverageMin (ref.)Avg (ref.)Max (ref.)Bioassay(s)
Chain A, Neutrophil gelatinase-associated lipocalinHomo sapiens (human)Kd0.00790.00790.00790.0079AID977611
[prepared from compound, protein, and bioassay information from National Library of Medicine (NLM), extracted Dec-2023]

Biological Processes (91)

Processvia Protein(s)Taxonomy
angiogenesis72 kDa type IV collagenaseHomo sapiens (human)
ovarian follicle development72 kDa type IV collagenaseHomo sapiens (human)
ovulation from ovarian follicle72 kDa type IV collagenaseHomo sapiens (human)
luteinization72 kDa type IV collagenaseHomo sapiens (human)
blood vessel maturation72 kDa type IV collagenaseHomo sapiens (human)
intramembranous ossification72 kDa type IV collagenaseHomo sapiens (human)
proteolysis72 kDa type IV collagenaseHomo sapiens (human)
negative regulation of cell adhesion72 kDa type IV collagenaseHomo sapiens (human)
heart development72 kDa type IV collagenaseHomo sapiens (human)
embryo implantation72 kDa type IV collagenaseHomo sapiens (human)
parturition72 kDa type IV collagenaseHomo sapiens (human)
response to xenobiotic stimulus72 kDa type IV collagenaseHomo sapiens (human)
response to mechanical stimulus72 kDa type IV collagenaseHomo sapiens (human)
peripheral nervous system axon regeneration72 kDa type IV collagenaseHomo sapiens (human)
response to activity72 kDa type IV collagenaseHomo sapiens (human)
protein metabolic process72 kDa type IV collagenaseHomo sapiens (human)
extracellular matrix disassembly72 kDa type IV collagenaseHomo sapiens (human)
protein catabolic process72 kDa type IV collagenaseHomo sapiens (human)
positive regulation of cell migration72 kDa type IV collagenaseHomo sapiens (human)
collagen catabolic process72 kDa type IV collagenaseHomo sapiens (human)
response to retinoic acid72 kDa type IV collagenaseHomo sapiens (human)
cellular response to reactive oxygen species72 kDa type IV collagenaseHomo sapiens (human)
response to nicotine72 kDa type IV collagenaseHomo sapiens (human)
endodermal cell differentiation72 kDa type IV collagenaseHomo sapiens (human)
response to hydrogen peroxide72 kDa type IV collagenaseHomo sapiens (human)
response to estrogen72 kDa type IV collagenaseHomo sapiens (human)
negative regulation of vasoconstriction72 kDa type IV collagenaseHomo sapiens (human)
ephrin receptor signaling pathway72 kDa type IV collagenaseHomo sapiens (human)
macrophage chemotaxis72 kDa type IV collagenaseHomo sapiens (human)
response to electrical stimulus72 kDa type IV collagenaseHomo sapiens (human)
response to hyperoxia72 kDa type IV collagenaseHomo sapiens (human)
face morphogenesis72 kDa type IV collagenaseHomo sapiens (human)
bone trabecula formation72 kDa type IV collagenaseHomo sapiens (human)
prostate gland epithelium morphogenesis72 kDa type IV collagenaseHomo sapiens (human)
cellular response to amino acid stimulus72 kDa type IV collagenaseHomo sapiens (human)
cellular response to interleukin-172 kDa type IV collagenaseHomo sapiens (human)
cellular response to estradiol stimulus72 kDa type IV collagenaseHomo sapiens (human)
cellular response to UV-A72 kDa type IV collagenaseHomo sapiens (human)
cellular response to fluid shear stress72 kDa type IV collagenaseHomo sapiens (human)
positive regulation of oxidative stress-induced neuron intrinsic apoptotic signaling pathway72 kDa type IV collagenaseHomo sapiens (human)
response to amyloid-beta72 kDa type IV collagenaseHomo sapiens (human)
positive regulation of vascular associated smooth muscle cell proliferation72 kDa type IV collagenaseHomo sapiens (human)
extracellular matrix organization72 kDa type IV collagenaseHomo sapiens (human)
response to hypoxia72 kDa type IV collagenaseHomo sapiens (human)
tissue remodeling72 kDa type IV collagenaseHomo sapiens (human)
membrane protein ectodomain proteolysisMatrilysinHomo sapiens (human)
membrane protein intracellular domain proteolysisMatrilysinHomo sapiens (human)
antibacterial peptide secretionMatrilysinHomo sapiens (human)
antibacterial peptide biosynthetic processMatrilysinHomo sapiens (human)
proteolysisMatrilysinHomo sapiens (human)
response to xenobiotic stimulusMatrilysinHomo sapiens (human)
extracellular matrix disassemblyMatrilysinHomo sapiens (human)
positive regulation of cell migrationMatrilysinHomo sapiens (human)
collagen catabolic processMatrilysinHomo sapiens (human)
regulation of cell population proliferationMatrilysinHomo sapiens (human)
defense response to Gram-negative bacteriumMatrilysinHomo sapiens (human)
defense response to Gram-positive bacteriumMatrilysinHomo sapiens (human)
extracellular matrix organizationMatrilysinHomo sapiens (human)
peptidyl-proline hydroxylation to 4-hydroxy-L-prolineProlyl 4-hydroxylase subunit alpha-1Gallus gallus (chicken)
protein glycosylation4-galactosyl-N-acetylglucosaminide 3-alpha-L-fucosyltransferase FUT6Homo sapiens (human)
protein N-linked glycosylation4-galactosyl-N-acetylglucosaminide 3-alpha-L-fucosyltransferase FUT6Homo sapiens (human)
protein O-linked glycosylation4-galactosyl-N-acetylglucosaminide 3-alpha-L-fucosyltransferase FUT6Homo sapiens (human)
ceramide metabolic process4-galactosyl-N-acetylglucosaminide 3-alpha-L-fucosyltransferase FUT6Homo sapiens (human)
glycosphingolipid biosynthetic process4-galactosyl-N-acetylglucosaminide 3-alpha-L-fucosyltransferase FUT6Homo sapiens (human)
oligosaccharide biosynthetic process4-galactosyl-N-acetylglucosaminide 3-alpha-L-fucosyltransferase FUT6Homo sapiens (human)
N-glycan fucosylation4-galactosyl-N-acetylglucosaminide 3-alpha-L-fucosyltransferase FUT6Homo sapiens (human)
L-fucose catabolic process4-galactosyl-N-acetylglucosaminide 3-alpha-L-fucosyltransferase FUT6Homo sapiens (human)
oocyte axis specification4-galactosyl-N-acetylglucosaminide 3-alpha-L-fucosyltransferase FUT6Homo sapiens (human)
regulation of type IV hypersensitivityAlpha-(1,3)-fucosyltransferase 7Homo sapiens (human)
CD4-positive, CD25-positive, alpha-beta regulatory T cell differentiationAlpha-(1,3)-fucosyltransferase 7Homo sapiens (human)
leukocyte migration involved in immune responseAlpha-(1,3)-fucosyltransferase 7Homo sapiens (human)
leukocyte migration involved in inflammatory responseAlpha-(1,3)-fucosyltransferase 7Homo sapiens (human)
protein glycosylationAlpha-(1,3)-fucosyltransferase 7Homo sapiens (human)
ceramide metabolic processAlpha-(1,3)-fucosyltransferase 7Homo sapiens (human)
inflammatory responseAlpha-(1,3)-fucosyltransferase 7Homo sapiens (human)
embryo implantationAlpha-(1,3)-fucosyltransferase 7Homo sapiens (human)
oligosaccharide biosynthetic processAlpha-(1,3)-fucosyltransferase 7Homo sapiens (human)
regulation of cell-cell adhesionAlpha-(1,3)-fucosyltransferase 7Homo sapiens (human)
positive regulation of cell-cell adhesionAlpha-(1,3)-fucosyltransferase 7Homo sapiens (human)
L-fucose catabolic processAlpha-(1,3)-fucosyltransferase 7Homo sapiens (human)
positive regulation of cell adhesionAlpha-(1,3)-fucosyltransferase 7Homo sapiens (human)
regulation of insulin receptor signaling pathwayAlpha-(1,3)-fucosyltransferase 7Homo sapiens (human)
regulation of cell adhesion molecule productionAlpha-(1,3)-fucosyltransferase 7Homo sapiens (human)
T cell migrationAlpha-(1,3)-fucosyltransferase 7Homo sapiens (human)
lymphocyte migration into lymph nodeAlpha-(1,3)-fucosyltransferase 7Homo sapiens (human)
positive regulation of neutrophil migrationAlpha-(1,3)-fucosyltransferase 7Homo sapiens (human)
regulation of leukocyte cell-cell adhesionAlpha-(1,3)-fucosyltransferase 7Homo sapiens (human)
regulation of leukocyte tethering or rollingAlpha-(1,3)-fucosyltransferase 7Homo sapiens (human)
positive regulation of leukocyte tethering or rollingAlpha-(1,3)-fucosyltransferase 7Homo sapiens (human)
positive regulation of leukocyte adhesion to vascular endothelial cellAlpha-(1,3)-fucosyltransferase 7Homo sapiens (human)
regulation of neutrophil extravasationAlpha-(1,3)-fucosyltransferase 7Homo sapiens (human)
fucosylationAlpha-(1,3)-fucosyltransferase 7Homo sapiens (human)
memory B cell differentiationCMP-N-acetylneuraminate-beta-galactosamide-alpha-2,3-sialyltransferase 1Homo sapiens (human)
N-acetylneuraminate metabolic processCMP-N-acetylneuraminate-beta-galactosamide-alpha-2,3-sialyltransferase 1Homo sapiens (human)
protein N-linked glycosylationCMP-N-acetylneuraminate-beta-galactosamide-alpha-2,3-sialyltransferase 1Homo sapiens (human)
ganglioside biosynthetic process via lactosylceramideCMP-N-acetylneuraminate-beta-galactosamide-alpha-2,3-sialyltransferase 1Homo sapiens (human)
O-glycan processingCMP-N-acetylneuraminate-beta-galactosamide-alpha-2,3-sialyltransferase 1Homo sapiens (human)
keratan sulfate biosynthetic processCMP-N-acetylneuraminate-beta-galactosamide-alpha-2,3-sialyltransferase 1Homo sapiens (human)
viral protein processingCMP-N-acetylneuraminate-beta-galactosamide-alpha-2,3-sialyltransferase 1Homo sapiens (human)
protein modification processCMP-N-acetylneuraminate-beta-galactosamide-alpha-2,3-sialyltransferase 1Homo sapiens (human)
sialylationCMP-N-acetylneuraminate-beta-galactosamide-alpha-2,3-sialyltransferase 1Homo sapiens (human)
negative regulation of activated CD8-positive, alpha-beta T cell apoptotic processCMP-N-acetylneuraminate-beta-galactosamide-alpha-2,3-sialyltransferase 1Homo sapiens (human)
protein sialylationCMP-N-acetylneuraminate-beta-galactosamide-alpha-2,3-sialyltransferase 1Homo sapiens (human)
protein glycosylationCMP-N-acetylneuraminate-beta-galactosamide-alpha-2,3-sialyltransferase 1Homo sapiens (human)
[Information is prepared from geneontology information from the June-17-2024 release]

Molecular Functions (16)

Processvia Protein(s)Taxonomy
fibronectin binding72 kDa type IV collagenaseHomo sapiens (human)
endopeptidase activity72 kDa type IV collagenaseHomo sapiens (human)
metalloendopeptidase activity72 kDa type IV collagenaseHomo sapiens (human)
serine-type endopeptidase activity72 kDa type IV collagenaseHomo sapiens (human)
protein binding72 kDa type IV collagenaseHomo sapiens (human)
metallopeptidase activity72 kDa type IV collagenaseHomo sapiens (human)
zinc ion binding72 kDa type IV collagenaseHomo sapiens (human)
endopeptidase activityMatrilysinHomo sapiens (human)
metalloendopeptidase activityMatrilysinHomo sapiens (human)
serine-type endopeptidase activityMatrilysinHomo sapiens (human)
protein bindingMatrilysinHomo sapiens (human)
metallopeptidase activityMatrilysinHomo sapiens (human)
zinc ion bindingMatrilysinHomo sapiens (human)
procollagen-proline 4-dioxygenase activityProlyl 4-hydroxylase subunit alpha-1Gallus gallus (chicken)
iron ion bindingProlyl 4-hydroxylase subunit alpha-1Gallus gallus (chicken)
L-ascorbic acid bindingProlyl 4-hydroxylase subunit alpha-1Gallus gallus (chicken)
fucosyltransferase activity4-galactosyl-N-acetylglucosaminide 3-alpha-L-fucosyltransferase FUT6Homo sapiens (human)
4-galactosyl-N-acetylglucosaminide 3-alpha-L-fucosyltransferase activity4-galactosyl-N-acetylglucosaminide 3-alpha-L-fucosyltransferase FUT6Homo sapiens (human)
alpha-(1->3)-fucosyltransferase activity4-galactosyl-N-acetylglucosaminide 3-alpha-L-fucosyltransferase FUT6Homo sapiens (human)
protein bindingAlpha-(1,3)-fucosyltransferase 7Homo sapiens (human)
fucosyltransferase activityAlpha-(1,3)-fucosyltransferase 7Homo sapiens (human)
4-galactosyl-N-acetylglucosaminide 3-alpha-L-fucosyltransferase activityAlpha-(1,3)-fucosyltransferase 7Homo sapiens (human)
alpha-(1->3)-fucosyltransferase activityAlpha-(1,3)-fucosyltransferase 7Homo sapiens (human)
beta-galactoside (CMP) alpha-2,3-sialyltransferase activityCMP-N-acetylneuraminate-beta-galactosamide-alpha-2,3-sialyltransferase 1Homo sapiens (human)
sialyltransferase activityCMP-N-acetylneuraminate-beta-galactosamide-alpha-2,3-sialyltransferase 1Homo sapiens (human)
beta-D-galactosyl-(1->3)-N-acetyl-beta-D-galactosaminide alpha-2,3- sialyltransferaseCMP-N-acetylneuraminate-beta-galactosamide-alpha-2,3-sialyltransferase 1Homo sapiens (human)
[Information is prepared from geneontology information from the June-17-2024 release]

Ceullar Components (20)

Processvia Protein(s)Taxonomy
collagen-containing extracellular matrix72 kDa type IV collagenaseHomo sapiens (human)
extracellular region72 kDa type IV collagenaseHomo sapiens (human)
extracellular space72 kDa type IV collagenaseHomo sapiens (human)
nucleus72 kDa type IV collagenaseHomo sapiens (human)
mitochondrion72 kDa type IV collagenaseHomo sapiens (human)
plasma membrane72 kDa type IV collagenaseHomo sapiens (human)
sarcomere72 kDa type IV collagenaseHomo sapiens (human)
collagen-containing extracellular matrix72 kDa type IV collagenaseHomo sapiens (human)
extracellular space72 kDa type IV collagenaseHomo sapiens (human)
extracellular regionMatrilysinHomo sapiens (human)
extracellular matrixMatrilysinHomo sapiens (human)
extracellular exosomeMatrilysinHomo sapiens (human)
extracellular spaceMatrilysinHomo sapiens (human)
endoplasmic reticulum lumenProlyl 4-hydroxylase subunit alpha-1Gallus gallus (chicken)
endoplasmic reticulumProlyl 4-hydroxylase subunit alpha-1Gallus gallus (chicken)
Golgi membrane4-galactosyl-N-acetylglucosaminide 3-alpha-L-fucosyltransferase FUT6Homo sapiens (human)
extracellular region4-galactosyl-N-acetylglucosaminide 3-alpha-L-fucosyltransferase FUT6Homo sapiens (human)
Golgi apparatus4-galactosyl-N-acetylglucosaminide 3-alpha-L-fucosyltransferase FUT6Homo sapiens (human)
Golgi cisterna membrane4-galactosyl-N-acetylglucosaminide 3-alpha-L-fucosyltransferase FUT6Homo sapiens (human)
extracellular exosome4-galactosyl-N-acetylglucosaminide 3-alpha-L-fucosyltransferase FUT6Homo sapiens (human)
methylosome4-galactosyl-N-acetylglucosaminide 3-alpha-L-fucosyltransferase FUT6Homo sapiens (human)
Golgi membraneAlpha-(1,3)-fucosyltransferase 7Homo sapiens (human)
Golgi apparatusAlpha-(1,3)-fucosyltransferase 7Homo sapiens (human)
trans-Golgi networkAlpha-(1,3)-fucosyltransferase 7Homo sapiens (human)
membraneAlpha-(1,3)-fucosyltransferase 7Homo sapiens (human)
Golgi cisterna membraneAlpha-(1,3)-fucosyltransferase 7Homo sapiens (human)
Golgi membraneCMP-N-acetylneuraminate-beta-galactosamide-alpha-2,3-sialyltransferase 1Homo sapiens (human)
membraneCMP-N-acetylneuraminate-beta-galactosamide-alpha-2,3-sialyltransferase 1Homo sapiens (human)
trans-Golgi network membraneCMP-N-acetylneuraminate-beta-galactosamide-alpha-2,3-sialyltransferase 1Homo sapiens (human)
extracellular exosomeCMP-N-acetylneuraminate-beta-galactosamide-alpha-2,3-sialyltransferase 1Homo sapiens (human)
Golgi medial cisterna membraneCMP-N-acetylneuraminate-beta-galactosamide-alpha-2,3-sialyltransferase 1Homo sapiens (human)
Golgi trans cisterna membraneCMP-N-acetylneuraminate-beta-galactosamide-alpha-2,3-sialyltransferase 1Homo sapiens (human)
membraneCMP-N-acetylneuraminate-beta-galactosamide-alpha-2,3-sialyltransferase 1Homo sapiens (human)
[Information is prepared from geneontology information from the June-17-2024 release]

Bioassays (52)

Assay IDTitleYearJournalArticle
AID588501High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Lethal Factor Protease, MLPCN compound set2010Current protocols in cytometry, Oct, Volume: Chapter 13Microsphere-based flow cytometry protease assays for use in protease activity detection and high-throughput screening.
AID588501High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Lethal Factor Protease, MLPCN compound set2006Cytometry. Part A : the journal of the International Society for Analytical Cytology, May, Volume: 69, Issue:5
Microsphere-based protease assays and screening application for lethal factor and factor Xa.
AID588501High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Lethal Factor Protease, MLPCN compound set2010Assay and drug development technologies, Feb, Volume: 8, Issue:1
High-throughput multiplex flow cytometry screening for botulinum neurotoxin type a light chain protease inhibitors.
AID588497High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain F protease, MLPCN compound set2010Current protocols in cytometry, Oct, Volume: Chapter 13Microsphere-based flow cytometry protease assays for use in protease activity detection and high-throughput screening.
AID588497High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain F protease, MLPCN compound set2006Cytometry. Part A : the journal of the International Society for Analytical Cytology, May, Volume: 69, Issue:5
Microsphere-based protease assays and screening application for lethal factor and factor Xa.
AID588497High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain F protease, MLPCN compound set2010Assay and drug development technologies, Feb, Volume: 8, Issue:1
High-throughput multiplex flow cytometry screening for botulinum neurotoxin type a light chain protease inhibitors.
AID651635Viability Counterscreen for Primary qHTS for Inhibitors of ATXN expression
AID1745845Primary qHTS for Inhibitors of ATXN expression
AID588499High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain A protease, MLPCN compound set2010Current protocols in cytometry, Oct, Volume: Chapter 13Microsphere-based flow cytometry protease assays for use in protease activity detection and high-throughput screening.
AID588499High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain A protease, MLPCN compound set2006Cytometry. Part A : the journal of the International Society for Analytical Cytology, May, Volume: 69, Issue:5
Microsphere-based protease assays and screening application for lethal factor and factor Xa.
AID588499High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain A protease, MLPCN compound set2010Assay and drug development technologies, Feb, Volume: 8, Issue:1
High-throughput multiplex flow cytometry screening for botulinum neurotoxin type a light chain protease inhibitors.
AID977611Experimentally measured binding affinity data (Kd) for protein-ligand complexes derived from PDB2012PloS one, , Volume: 7, Issue:8
Siderocalin/Lcn2/NGAL/24p3 does not drive apoptosis through gentisic acid mediated iron withdrawal in hematopoietic cell lines.
AID566701Inhibition of recombinant anthrax lethal factor at 1 mM after 30 mins by fluorescence assay2011Journal of medicinal chemistry, Jan-27, Volume: 54, Issue:2
Identifying chelators for metalloprotein inhibitors using a fragment-based approach.
AID566703Inhibition of human recombinant MMP2 at 1 mM after 30 mins2011Journal of medicinal chemistry, Jan-27, Volume: 54, Issue:2
Identifying chelators for metalloprotein inhibitors using a fragment-based approach.
AID566699Inhibition of mushroom tyrosinase at 1 mM after 10 mins2011Journal of medicinal chemistry, Jan-27, Volume: 54, Issue:2
Identifying chelators for metalloprotein inhibitors using a fragment-based approach.
AID977599Inhibition of sodium fluorescein uptake in OATP1B1-transfected CHO cells at an equimolar substrate-inhibitor concentration of 10 uM2013Molecular pharmacology, Jun, Volume: 83, Issue:6
Structure-based identification of OATP1B1/3 inhibitors.
AID566704Inhibition of human recombinant MMP3 at 1 mM after 30 mins2011Journal of medicinal chemistry, Jan-27, Volume: 54, Issue:2
Identifying chelators for metalloprotein inhibitors using a fragment-based approach.
AID338333Antiplatelet activity against rat platelet rich plasma assessed as inhibition of arachidonic acid-induced platelet aggregation at 0.5 mg/ml pretreated 2 mins before arachidonic acid challenge
AID1363739Inhibition of Influenza A (A/California/04/2009) (H1N1) clinical isolate N-terminal truncated PA endonuclease using 5'-FAM/3-TAMRA quencer labeled 17-mer ssDNA-oligo as substrate measured over 45 mins by FRET assay2018Journal of medicinal chemistry, 11-21, Volume: 61, Issue:22
Structure-Activity Relationships in Metal-Binding Pharmacophores for Influenza Endonuclease.
AID338335Antiplatelet activity against rat platelet rich plasma assessed as inhibition of arachidonic acid-induced platelet aggregation at 0.25 mg/ml pretreated 2 mins before arachidonic acid challenge
AID280295Inhibition of attachment of HL60 cells to E-selectin at 109 uM after 5 mins2007Journal of medicinal chemistry, Mar-22, Volume: 50, Issue:6
Rational design of novel, potent small molecule pan-selectin antagonists.
AID280294Inhibition of human L-selectin after 2 hrs at 100 uM2007Journal of medicinal chemistry, Mar-22, Volume: 50, Issue:6
Rational design of novel, potent small molecule pan-selectin antagonists.
AID566706Inhibition of human recombinant MMP9 at 1 mM after 30 mins2011Journal of medicinal chemistry, Jan-27, Volume: 54, Issue:2
Identifying chelators for metalloprotein inhibitors using a fragment-based approach.
AID1363741Inhibition of full length human arginase 1 expressed in Escherichia coli BL21(DE3) at 200 uM using unlabeled L-arginine/L-[guanidino-14C]arginine as substrate after 5 mins by liquid scintillation counting method relative to control2018Journal of medicinal chemistry, 11-21, Volume: 61, Issue:22
Structure-Activity Relationships in Metal-Binding Pharmacophores for Influenza Endonuclease.
AID566705Inhibition of human recombinant MMP8 at 1 mM after 30 mins2011Journal of medicinal chemistry, Jan-27, Volume: 54, Issue:2
Identifying chelators for metalloprotein inhibitors using a fragment-based approach.
AID1363740Inhibition of Influenza A (A/California/04/2009) (H1N1) clinical isolate N-terminal truncated PA endonuclease at 500 nM using 5'-FAM/3-TAMRA quencer labeled 17-mer ssDNA-oligo as substrate measured over 45 mins by FRET assay relative to control2018Journal of medicinal chemistry, 11-21, Volume: 61, Issue:22
Structure-Activity Relationships in Metal-Binding Pharmacophores for Influenza Endonuclease.
AID1363742Inhibition of bacterial NDM1 at 200 uM using chromacef as substrate preincubated for 10 mins followed by substrate addition2018Journal of medicinal chemistry, 11-21, Volume: 61, Issue:22
Structure-Activity Relationships in Metal-Binding Pharmacophores for Influenza Endonuclease.
AID1449689Cytotoxicity against HEK293 cells harboring pendrin P123S mutant assessed as decrease in cell viability at 15 mM after 72 hrs by MTT assay2017Bioorganic & medicinal chemistry, 05-01, Volume: 25, Issue:9
Discovery of (2-aminophenyl)methanol as a new molecular chaperone that rescues the localization of P123S mutant pendrin stably expressed in HEK293 cells.
AID1374856Antiproliferative activity against human HeLa cells after 48 hrs by CCK8 assay2018Bioorganic & medicinal chemistry letters, 04-01, Volume: 28, Issue:6
Two new coumarins and a new xanthone from the leaves of Rhizophora mucronata.
AID566702Inhibition of human recombinant MMP1 at 1 mM after 30 mins2011Journal of medicinal chemistry, Jan-27, Volume: 54, Issue:2
Identifying chelators for metalloprotein inhibitors using a fragment-based approach.
AID280290Inhibition of human E-selectin after 2 hrs at 100 uM2007Journal of medicinal chemistry, Mar-22, Volume: 50, Issue:6
Rational design of novel, potent small molecule pan-selectin antagonists.
AID1248399Inhibition of alpha-amylase (unknown origin) relative to control2015Bioorganic & medicinal chemistry, Oct-15, Volume: 23, Issue:20
From carbohydrates to drug-like fragments: Rational development of novel α-amylase inhibitors.
AID338339Antiplatelet activity against rat platelet rich plasma assessed as inhibition of ADP-induced platelet aggregation at 1 mg/ml pretreated 2 mins before ADP challenge
AID385427Inhibition of soybean 15-lipoxygenase2008Bioorganic & medicinal chemistry, Apr-15, Volume: 16, Issue:8
Inhibition of 15-lipoxygenase-catalysed oxygenation of arachidonic acid by substituted benzoic acids.
AID1363750Inhibition of human MetAP2 Mn2+ isoform at 200 uM using Met-AMC as substrate by fluorescence assay relative to control2018Journal of medicinal chemistry, 11-21, Volume: 61, Issue:22
Structure-Activity Relationships in Metal-Binding Pharmacophores for Influenza Endonuclease.
AID566700Inhibition of human recombinant 5-lipoxygenase at 1 mM after 10 mins by fluorescence assay2011Journal of medicinal chemistry, Jan-27, Volume: 54, Issue:2
Identifying chelators for metalloprotein inhibitors using a fragment-based approach.
AID280296Inhibition of attachment of HL60 cells to P-selectin at 109 uM after 5 mins2007Journal of medicinal chemistry, Mar-22, Volume: 50, Issue:6
Rational design of novel, potent small molecule pan-selectin antagonists.
AID1374857Antiproliferative activity against human HL60 cells after 48 hrs by CCK8 assay2018Bioorganic & medicinal chemistry letters, 04-01, Volume: 28, Issue:6
Two new coumarins and a new xanthone from the leaves of Rhizophora mucronata.
AID977602Inhibition of sodium fluorescein uptake in OATP1B3-transfected CHO cells at an equimolar substrate-inhibitor concentration of 10 uM2013Molecular pharmacology, Jun, Volume: 83, Issue:6
Structure-based identification of OATP1B1/3 inhibitors.
AID338336Antiplatelet activity against rat platelet rich plasma assessed as inhibition of collagen-induced platelet aggregation at 0.25 mg/ml pretreated 2 mins before collagen challenge
AID462433Induction of neuritogenic activity in rat PC12 cells assessed as long neurite outgrowths at 1 to 30 uM after 48 hrs2010Bioorganic & medicinal chemistry, Mar-15, Volume: 18, Issue:6
Gentisides A and B, two new neuritogenic compounds from the traditional Chinese medicine Gentiana rigescens Franch.
AID447578Inhibition of HDAC in human Hela cells nuclear extracts assessed as residual activity at 500 uM by fluorimetric assay2009Bioorganic & medicinal chemistry, Jul-15, Volume: 17, Issue:14
Molecular modifications on carboxylic acid derivatives as potent histone deacetylase inhibitors: Activity and docking studies.
AID566707Inhibition of mouse recombinant iNOS at 1 mM after 40 mins by colorimetric assay2011Journal of medicinal chemistry, Jan-27, Volume: 54, Issue:2
Identifying chelators for metalloprotein inhibitors using a fragment-based approach.
AID280292Inhibition of human P-selectin after 2 hrs at 100 uM2007Journal of medicinal chemistry, Mar-22, Volume: 50, Issue:6
Rational design of novel, potent small molecule pan-selectin antagonists.
AID1449688Cytotoxicity against HEK293 cells harboring pendrin P123S mutant after 72 hrs by MTT assay2017Bioorganic & medicinal chemistry, 05-01, Volume: 25, Issue:9
Discovery of (2-aminophenyl)methanol as a new molecular chaperone that rescues the localization of P123S mutant pendrin stably expressed in HEK293 cells.
AID492404Binding affinity to human serum albumin in 100 mM phosphate buffer at pH 7.4 assessed as formation of biotin-LC-hydrazide labeled protein carbonyls at 100 uM pretreated 60 mins before biotin-LC-hydrazide challenge measured after 60 mins by SDS-PAGE/Wester2010Bioorganic & medicinal chemistry, Jul-15, Volume: 18, Issue:14
Structural characteristics of green tea catechins for formation of protein carbonyl in human serum albumin.
AID1449696Chaperone activity at recombinant human C-terminal FLAG-tagged pendrin P123S mutant expressed in HEK293 cells assessed as increase in localization of protein mutant in plasma membrane at 1 to 30 mM after 12 hrs by DAPI staining based immunofluorescence mi2017Bioorganic & medicinal chemistry, 05-01, Volume: 25, Issue:9
Discovery of (2-aminophenyl)methanol as a new molecular chaperone that rescues the localization of P123S mutant pendrin stably expressed in HEK293 cells.
AID1799773SPA Assay from Article 10.1016/j.abb.2004.02.039: \\Inhibition of fucosyltransferase VII by gallic acid and its derivatives.\\2004Archives of biochemistry and biophysics, May-01, Volume: 425, Issue:1
Inhibition of fucosyltransferase VII by gallic acid and its derivatives.
AID1799825Inhibition Assay from Article : \\Partial identity of the 2-oxoglutarate and ascorbate binding sites of prolyl 4-hydroxylase.\\1986The Journal of biological chemistry, Jun-15, Volume: 261, Issue:17
Partial identity of the 2-oxoglutarate and ascorbate binding sites of prolyl 4-hydroxylase.
AID1159550Human Phosphogluconate dehydrogenase (6PGD) Inhibitor Screening2015Nature cell biology, Nov, Volume: 17, Issue:11
6-Phosphogluconate dehydrogenase links oxidative PPP, lipogenesis and tumour growth by inhibiting LKB1-AMPK signalling.
AID977611Experimentally measured binding affinity data (Kd) for protein-ligand complexes derived from PDB2002Molecular cell, Nov, Volume: 10, Issue:5
The neutrophil lipocalin NGAL is a bacteriostatic agent that interferes with siderophore-mediated iron acquisition.
AID1811Experimentally measured binding affinity data derived from PDB2002Molecular cell, Nov, Volume: 10, Issue:5
The neutrophil lipocalin NGAL is a bacteriostatic agent that interferes with siderophore-mediated iron acquisition.
[information is prepared from bioassay data collected from National Library of Medicine (NLM), extracted Dec-2023]

Research

Studies (421)

TimeframeStudies, This Drug (%)All Drugs %
pre-199040 (9.50)18.7374
1990's142 (33.73)18.2507
2000's152 (36.10)29.6817
2010's72 (17.10)24.3611
2020's15 (3.56)2.80
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Market Indicators

Research Demand Index: 30.96

According to the monthly volume, diversity, and competition of internet searches for this compound, as well the volume and growth of publications, there is estimated to be moderate demand-to-supply ratio for research on this compound.

MetricThis Compound (vs All)
Research Demand Index30.96 (24.57)
Research Supply Index6.09 (2.92)
Research Growth Index4.87 (4.65)
Search Engine Demand Index40.78 (26.88)
Search Engine Supply Index2.00 (0.95)

This Compound (30.96)

All Compounds (24.57)

Study Types

Publication TypeThis drug (%)All Drugs (%)
Trials4 (0.92%)5.53%
Reviews7 (1.60%)6.00%
Case Studies0 (0.00%)4.05%
Observational0 (0.00%)0.25%
Other426 (97.48%)84.16%
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]